sur INVENTIVA (EPA:IVA)
Inventiva Announces 2024 Full-Year Financial Results Schedule
Inventiva, a clinical-stage biopharmaceutical company, will release its 2024 full-year financial results on March 26, 2025. The results will be published at 4:00 pm New York time, and 9:00 pm Paris time. The following day, March 27, 2025, CEO Frédéric Cren and CFO Jean Volatier will host a webcast to present these results.
The presentation will occur at 8:00 am in New York and 1:00 pm in Paris, featuring a Q&A session. Participants must register in advance to access the conference, using details provided in a confirmation email. A replay will be accessible on Inventiva's website afterward.
Inventiva focuses on developing oral small molecule therapies for treating MASH and other conditions with unmet medical needs. Their developments include lanifibranor, currently in Phase 3 clinical trials for MASH treatment.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de INVENTIVA